title: Can we ignore minimal hepatic encephalopathy any longer?
authors.forename: Asif M
authors.initials: AM
authors.lastname: Qadri
authors.forename: Ben O
authors.initials: BO
authors.lastname: Ogunwale
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Mullen
mesh_terms: D004187:Disaccharides / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology*; D006801:Humans; D015994:Incidence; D007792:Lactulose / Q000009:adverse effects / Q000627:therapeutic use; D011594:Psychometrics; D011788:Quality of Life / Q000523:psychology*; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D004187:Disaccharides; D005765:Gastrointestinal Agents; D012294:Rifamycins; D007792:Lactulose; D000078262:Rifaximin